JPRN-jRCT2080220811未知2 期
A Phase II, Multicenter, Clinical Trial to Evaluate The Efficacy and Safety of Bevacizumab in Recurrent Malignant Glioma
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Age >= 20 years
- •-Histologically confirmed malignant glioma
- •-All patients must have received prior temozolomide and prior radiation therapy for malignant glioma.
- •-No evidence of recent hemorrhage on baseline MRI of the brain.
- •-Karnofsky Performance Status >= 70%
排除标准
- •-The patient has received more than two regimens for malignant glioma.
- •-History of hemoptysis(>=Grade2) within 1 month before randomization.
- •-Serious non-healing wound or untreated bone fracture.
研究者
相似试验
招募中
1 期
Phase 2 Study of MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular CarcinomaHepatocellular carcinomaCTIS2023-505698-34-00Merck Sharp & Dohme LLC102
进行中（未招募）
1 期
Phase 2 Study of MK 1308A (Coformulated MK 1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular CarcinomaAdvanced hepatocellular carcinoma without any prior systemic treatmentMedDRA version: 20.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004490-52-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.110
进行中（未招募）
2 期
Phase 2 Study of MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular CarcinomaAdvanced hepatocellular carcinomaJPRN-jRCT2061210033Hoki Toshifumi6
进行中（未招募）
1 期
Phase 2 Study of MK 1308A (Coformulated MK 1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular CarcinomaEUCTR2020-004490-52-PLMerck Sharp & Dohme LLC110
已完成
2 期
The safety of Cpn10 in patients with multiple sclerosisNeurological - Multiple sclerosisMultiple SclerosisACTRN12606000037505CBio Limited50